The FDA did not agree..
With Resapp best practice...
The recent studies indicate Doctor's are poor at making respiratory diagnosis ...
The US Resapp dx trial also highlighted the poor diagnostic skills of expert respiratory doctor's...
None could agree with each other ...
The technical limitations in respiratory diagnosis are Doctor's.
The US are deep in Covid crisis once more ...
I feel that it will not be long before the FDA see the error of their decision.
MB
- Forums
- ASX - By Stock
- RAP
- Ann: Publication on challenges of diagnosing respiratory disease
Ann: Publication on challenges of diagnosing respiratory disease, page-27
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)